Price Chart

Profile

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
URL https://www.blueprintmedicines.com
Investor Relations URL https://ir.blueprintmedicines.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
URL https://www.blueprintmedicines.com
Investor Relations URL https://ir.blueprintmedicines.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A